RE: Looks25 Jun 2018 10:30
As per RNS the quote from Dr Chris Blackwell sum's it up "Exciting time and to support the management team with the development of its drug pipeline, particularly given Nuformix's approach to diseases such as fibrosis, with its NXP002 programme, targeting large unmet needs in therapeutic markets with significant commercial potential."
Its definately a rerate on cards to double Digit GLA